A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma

PURPOSE: Therapy resistance and fatal disease progression in glioblastoma are thought to result from the dynamics of intra-tumor heterogeneity. This study aimed at identifying and molecularly targeting tumor cells that can survive, adapt, and subclonally expand under primary therapy. EXPERIMENTAL DE...

Descripción completa

Detalles Bibliográficos
Autores principales: Kebir, Sied, Ullrich, Vivien, Berger, Pia, Dobersalske, Celia, Langer, Sarah, Rauschenbach, Laurèl, Trageser, Daniel, Till, Andreas, Lorbeer, Franziska K., Wieland, Anja, Wilhelm-Buchstab, Timo, Ahmad, Ashar, Fröhlich, Holger, Cima, Igor, Prasad, Shruthi, Matschke, Johann, Jendrossek, Verena, Remke, Marc, Grüner, Barbara M., Roesch, Alexander, Siveke, Jens T., Herold-Mende, Christel, Blau, Tobias, Keyvani, Kathy, van Landeghem, Frank K.H., Pietsch, Torsten, Felsberg, Jörg, Reifenberger, Guido, Weller, Michael, Sure, Ulrich, Brüstle, Oliver, Simon, Matthias, Glas, Martin, Scheffler, Björn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843437/
https://www.ncbi.nlm.nih.gov/pubmed/36239995
http://dx.doi.org/10.1158/1078-0432.CCR-22-0611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843437/
https://www.ncbi.nlm.nih.gov/pubmed/36239995
http://dx.doi.org/10.1158/1078-0432.CCR-22-0611

Ejemplares similares